[A15-53] Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2016
Project no.:
A15-53
Commission:
Commission awarded on 14.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-08 | Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A15-20 | Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A20-78 | Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-79 | Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-80 | Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-69 | Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V | Commission completed |
| A22-68 | Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-06-02 A G-BA decision was published.